Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study-Reference-Cited by-同舟云学术

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Published:2015-03 Issue:3 Volume:16 Page:328-337
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Paz-Ares Luis,Mezger Jörg,Ciuleanu Tudor E,Fischer Jürgen R,von Pawel Joachim,Provencio Mariano,Kazarnowicz Andrzej,Losonczy György,de Castro Gilberto,Szczesna Aleksandra,Crino Lucio,Reck Martin,Ramlau Rodryg,Ulsperger Ernst,Schumann Christian,Miziara Jose Elias A,Lessa Álvaro E,Dediu Mircea,Bálint Beatrix,Depenbrock Henrik,Soldatenkova Victoria,Kurek Raffael,Hirsch Fred R,Thatcher Nick,Socinski Mark A

Funder

Fondo de Investigación Sanitaria

Publisher

Elsevier BV

Subject

Oncology

Reference37 articles.

1. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials;Travis;J Clin Oncol,2013

2. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma;Thomas;Ann Oncol,2013

3. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

4. Molecular biology of lung cancer;Cooper;J Thorac Dis,2013

5. Management and future directions in non-small cell lung cancer with known activating mutations;Gerber;Am Soc Clin Oncol Educ Book,2014

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung;Gene;2024-02

2. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01

3. Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review;International Journal of Biological Macromolecules;2023-12

4. Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers;Molecular Therapy - Oncolytics;2023-12

5. Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy;Journal of Controlled Release;2023-09